Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 18, 2022 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board

SEATTLE, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
July 28, 2022 09:00 ET | Source: Atossa Therapeutics, Inc.

Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
April 20, 2022 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20, 2022 (GLOBE...
January 27, 2022 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
January 18, 2022 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
September 30, 2021 09:30 ET | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia

SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...